Inflammatory knee osteoarthritis
Conditions
Interventions
treatment group:Etanercept
control group:Nonsteroidal anti-inflammatory drugs
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
38 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Ages 38 to 70, no gender restrictions. 2.The diagnosis meets the classification criteria for knee osteoarthritis revised in 1995 by the American College of Rheumatology.. 3.The patient agrees to the study treatment protocol, understands the trial procedures and content, and voluntarily signs the informed consent form to indicate their willingness to participate in the trial. 4.Based on the ROAMES score, the target joint belongs to patients with inflammatory osteoarthritis. 5.Eligibility for DMARDs can be determined through a tuberculosis screening and an evaluation by a physician.
Exclusion criteria
Exclusion criteria: 1.Knee X-ray evaluation shows a K-L grade IV. 2.RF or anti-CCP antibody levels exceed twice the normal upper limit; Anti-nuclear antibodies >= 1:320. 3.Combining infectious arthritis, gout, spondyloarthritis, or seronegative rheumatoid arthritis. 4.Positive for hepatitis B surface antigen or alanine aminotransferase or creatinine levels greater than 1.5 times the upper limit of normal. 5.Pregnant or breastfeeding women; 6.Patients with late-stage osteonecrosis, severe knee valgus or varus deformities, severe subchondral cystic lesions, or fractures of the femur or tibia. 7.Patients who have used DMARDs or medications containing chondroitin sulfate, glucosamine, or diacerein within the last three months, or who have received hyaluronic acid or corticosteroid joint cavity treatments in the past four weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| level of pain; | — |
Countries
China
Contacts
Public ContactHelan
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed